130 related articles for article (PubMed ID: 7566976)
1. Resistance to Fas-mediated apoptosis in human hepatoma cells.
Natoli G; Ianni A; Costanzo A; De Petrillo G; Ilari I; Chirillo P; Balsano C; Levrero M
Oncogene; 1995 Sep; 11(6):1157-64. PubMed ID: 7566976
[TBL] [Abstract][Full Text] [Related]
2. Fas/APO-1 gene transfer for human malignant glioma.
Weller M; Malipiero U; Rensing-Ehl A; Barr PJ; Fontana A
Cancer Res; 1995 Jul; 55(13):2936-44. PubMed ID: 7540953
[TBL] [Abstract][Full Text] [Related]
3. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
4. Fas-mediated apoptosis in human prostatic carcinoma cell lines.
Rokhlin OW; Bishop GA; Hostager BS; Waldschmidt TJ; Sidorenko SP; Pavloff N; Kiefer MC; Umansky SR; Glover RA; Cohen MB
Cancer Res; 1997 May; 57(9):1758-68. PubMed ID: 9135020
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways.
Jiang S; Song MJ; Shin EC; Lee MO; Kim SJ; Park JH
Hepatology; 1999 Jan; 29(1):101-10. PubMed ID: 9862856
[TBL] [Abstract][Full Text] [Related]
6. Activation of caspase-8 during N-(4-hydroxyphenyl)retinamide-induced apoptosis in Fas-defective hepatoma cells.
You KR; Shin MN; Park RK; Lee SO; Kim DG
Hepatology; 2001 Dec; 34(6):1119-27. PubMed ID: 11732001
[TBL] [Abstract][Full Text] [Related]
7. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis.
von Reyher U; Sträter J; Kittstein W; Gschwendt M; Krammer PH; Möller P
Cancer Res; 1998 Feb; 58(3):526-34. PubMed ID: 9458101
[TBL] [Abstract][Full Text] [Related]
8. Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis.
Mori S; Murakami-Mori K; Jewett A; Nakamura S; Bonavida B
Cancer Res; 1996 Apr; 56(8):1874-9. PubMed ID: 8620507
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
Uslu R; Borsellino N; Frost P; Gárban H; Ng CP; Mizutani Y; Belldegrun A; Bonavida B
Clin Cancer Res; 1997 Jun; 3(6):963-72. PubMed ID: 9815772
[TBL] [Abstract][Full Text] [Related]
10. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells.
Fukazawa T; Fujiwara T; Morimoto Y; Shao J; Nishizaki M; Kadowaki Y; Hizuta A; Owen-Schaub LB; Roth JA; Tanaka N
Oncogene; 1999 Apr; 18(13):2189-99. PubMed ID: 10327065
[TBL] [Abstract][Full Text] [Related]
11. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
[TBL] [Abstract][Full Text] [Related]
12. Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells.
Shao RG; Cao CX; Nieves-Neira W; Dimanche-Boitrel MT; Solary E; Pommier Y
Oncogene; 2001 Apr; 20(15):1852-9. PubMed ID: 11313933
[TBL] [Abstract][Full Text] [Related]
13. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression.
Fulda S; Meyer E; Debatin KM
Cancer Res; 2000 Jul; 60(14):3947-56. PubMed ID: 10919673
[TBL] [Abstract][Full Text] [Related]
14. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M
J Hepatol; 2007 Jan; 46(1):77-88. PubMed ID: 17045692
[TBL] [Abstract][Full Text] [Related]
15. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
[TBL] [Abstract][Full Text] [Related]
16. Apoptotic behaviour of hepatic and extra-hepatic tumor cell lines differs after Fas stimulation.
Lamboley C; Bringuier AF; Feldmann G
Cell Mol Biol (Noisy-le-grand); 2000 Feb; 46(1):13-28. PubMed ID: 10726968
[TBL] [Abstract][Full Text] [Related]
17. Conversion of Fas-resistant to Fas-sensitive MCF-7 breast cancer cells by the synergistic interaction of interferon-gamma and all-trans retinoic acid.
Danforth DN; Zhu Y
Breast Cancer Res Treat; 2005 Nov; 94(1):81-91. PubMed ID: 16136269
[TBL] [Abstract][Full Text] [Related]
18. Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control.
Gerharz CD; Ramp U; Déjosez M; Mahotka C; Czarnotta B; Bretschneider U; Lorenz I; Müller M; Krammer PH; Gabbert HE
Lab Invest; 1999 Dec; 79(12):1521-34. PubMed ID: 10616203
[TBL] [Abstract][Full Text] [Related]
19. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro.
Papoff G; Cascino I; Eramo A; Starace G; Lynch DH; Ruberti G
J Immunol; 1996 Jun; 156(12):4622-30. PubMed ID: 8648105
[TBL] [Abstract][Full Text] [Related]
20. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis.
Cascino I; Papoff G; De Maria R; Testi R; Ruberti G
J Immunol; 1996 Jan; 156(1):13-7. PubMed ID: 8598453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
